• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性ST2作为接受球囊肺动脉血管成形术治疗的慢性血栓栓塞性肺动脉高压患者早期并发症的生物标志物

Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.

作者信息

Banaszkiewicz Marta, Pietrasik Arkadiusz, Florczyk Michał, Kędzierski Piotr, Piłka Michał, Mańczak Rafał, Kochman Janusz, Opolski Grzegorz, Torbicki Adam, Kurzyna Marcin, Darocha Szymon

机构信息

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Center Otwock, 05-400 Otwock, Poland.

Department and Faculty of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.

出版信息

Diagnostics (Basel). 2021 Jan 16;11(1):133. doi: 10.3390/diagnostics11010133.

DOI:10.3390/diagnostics11010133
PMID:33467121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7830401/
Abstract

BACKGROUND

The aim of the study was to assess soluble ST2 (sST2) concentration and its dynamic changes in the periprocedural period in patients with chronic thromboembolic pulmonary hypertension (CTEPH) treated with balloon pulmonary angioplasty (BPA).

METHODS

We prospectively analyzed 57 procedures of BPA performed in 37 patients with CTEPH. Biomarkers, such as N-terminal pro B-type natriuretic peptide (NT-proBNP), troponin T (TnT), and sST2 were assessed at four time points: Before the BPA procedure, 24 h and 48 h after the procedure, and at the discharge from hospital. Each postprocedural period was assessed for complications.

RESULTS

Before the BPA procedure, median sST2 concentration was 26.56 ng/mL (IQR: 16.66-40.83 ng/mL). sST2 concentration was significantly higher 24 h and 48 h after the BPA compared to the baseline measurements (33.31 ng/mL (IQR: 20.81-62.56), = 0.000 and 27.45 ng/mL (IQR: 17.66-54.45), = 0.028, respectively). sST2 level 24 h after the BPA procedure was significantly higher in the group with complications compared to the group without complications in the postprocedural period (97.66 ng/mL (IQR: 53.07-126.18) vs. 26.86 ng/mL (IQR: 19.10-40.12), = 0.000).

CONCLUSIONS

sST2 concentration in patients with CTEPH treated with BPA changes significantly in the postprocedural period and is significantly higher in the group with complications in postprocedural period.

摘要

背景

本研究旨在评估接受球囊肺动脉血管成形术(BPA)治疗的慢性血栓栓塞性肺动脉高压(CTEPH)患者围手术期可溶性ST2(sST2)浓度及其动态变化。

方法

我们前瞻性分析了37例CTEPH患者接受的57次BPA手术。在四个时间点评估生物标志物,如N末端B型利钠肽原(NT-proBNP)、肌钙蛋白T(TnT)和sST2:BPA手术前、手术后24小时和48小时以及出院时。对每个术后阶段的并发症进行评估。

结果

BPA手术前,sST2浓度中位数为26.56 ng/mL(四分位间距:16.66 - 40.83 ng/mL)。与基线测量值相比,BPA术后24小时和48小时sST2浓度显著更高(分别为33.31 ng/mL(四分位间距:20.81 - 62.56),P = 0.000和27.45 ng/mL(四分位间距:17.66 - 54.45),P = 0.028)。术后24小时,术后出现并发症的组sST2水平显著高于未出现并发症的组(97.66 ng/mL(四分位间距:53.07 - 126.18) vs. 26.86 ng/mL(四分位间距:19.10 - 40.12),P = 0.000)。

结论

接受BPA治疗的CTEPH患者术后sST2浓度发生显著变化,且术后出现并发症的组sST2浓度显著更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9867/7830401/ad41f3a94ae6/diagnostics-11-00133-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9867/7830401/c77e9447eb92/diagnostics-11-00133-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9867/7830401/ad41f3a94ae6/diagnostics-11-00133-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9867/7830401/c77e9447eb92/diagnostics-11-00133-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9867/7830401/ad41f3a94ae6/diagnostics-11-00133-g002.jpg

相似文献

1
Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.可溶性ST2作为接受球囊肺动脉血管成形术治疗的慢性血栓栓塞性肺动脉高压患者早期并发症的生物标志物
Diagnostics (Basel). 2021 Jan 16;11(1):133. doi: 10.3390/diagnostics11010133.
2
Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压期间高敏心肌肌钙蛋白 T 的动态变化。
PLoS One. 2018 Sep 25;13(9):e0204683. doi: 10.1371/journal.pone.0204683. eCollection 2018.
3
N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.N 末端 pro-B 型利钠肽在慢性血栓栓塞性肺动脉高压球囊肺血管成形术后的监测作用。
J Heart Lung Transplant. 2018 May;37(5):639-646. doi: 10.1016/j.healun.2017.12.006. Epub 2017 Dec 8.
4
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience.球囊肺动脉血管成形术治疗慢性血栓栓塞性肺动脉高压:单中心初步经验
Mayo Clin Proc Innov Qual Outcomes. 2019 Aug 23;3(3):311-318. doi: 10.1016/j.mayocpiqo.2019.06.006. eCollection 2019 Sep.
5
[Efficacy and safety of Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension].球囊肺动脉血管成形术治疗慢性血栓栓塞性肺动脉高压的疗效与安全性
Zhonghua Yi Xue Za Zhi. 2020 Feb 18;100(6):437-441. doi: 10.3760/cma.j.issn.0376-2491.2020.06.008.
6
Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.球囊肺血管成形术治疗无法手术的慢性血栓栓塞性肺动脉高压患者。
Heart. 2013 Oct;99(19):1415-20. doi: 10.1136/heartjnl-2012-303549. Epub 2013 Jul 11.
7
Balloon pulmonary angioplasty is effective for treating peripheral-type chronic thromboembolic pulmonary hypertension in elderly patients.球囊肺血管成形术治疗老年外周型慢性血栓栓塞性肺动脉高压有效。
Geriatr Gerontol Int. 2018 May;18(5):678-684. doi: 10.1111/ggi.13224. Epub 2017 Dec 26.
8
Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty.球囊肺动脉成形术治疗无法手术的慢性血栓栓塞性肺动脉高压患者的血流动力学和心肺功能改善。
Respir Res. 2019 Nov 8;20(1):250. doi: 10.1186/s12931-019-1211-y.
9
Balloon Pulmonary Angioplasty in Technically Operable and Technically Inoperable Chronic Thromboembolic Pulmonary Hypertension.技术上可操作及技术上不可操作的慢性血栓栓塞性肺动脉高压的球囊肺动脉血管成形术
J Clin Med. 2021 Mar 3;10(5):1038. doi: 10.3390/jcm10051038.
10
Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands.荷兰球囊肺动脉血管成形术治疗慢性血栓栓塞性肺动脉高压的安全性和有效性
Neth Heart J. 2020 Feb;28(2):81-88. doi: 10.1007/s12471-019-01352-6.

引用本文的文献

1
Emerging Role of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease-Insights from the 2022 ESC Guidelines.球囊肺血管成形术在慢性血栓栓塞性肺疾病中的新作用——来自2022年欧洲心脏病学会指南的见解
J Clin Med. 2023 Aug 16;12(16):5336. doi: 10.3390/jcm12165336.
2
Biomarkers in Pulmonary Arterial Hypertension.肺动脉高压中的生物标志物
Diagnostics (Basel). 2022 Dec 3;12(12):3033. doi: 10.3390/diagnostics12123033.
3
Using a Fibrinolysis Delivery Catheter in Pulmonary Embolism Treatment for Measurement of Pulmonary Artery Hemodynamics.

本文引用的文献

1
Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension.半乳糖凝集素-3、生长分化因子 15 和可溶性 ST2 用于评估无法手术的慢性血栓栓塞性肺动脉高压患者的疾病严重程度和治疗反应。
Biomarkers. 2020 Nov;25(7):578-586. doi: 10.1080/1354750X.2020.1821776. Epub 2020 Sep 22.
2
Treatment of chronic thromboembolic pulmonary hypertension in a multidisciplinary team.多学科团队治疗慢性血栓栓塞性肺动脉高压。
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619891529. doi: 10.1177/1753466619891529.
3
The Prognostic Value of Soluble ST2 in Adults with Pulmonary Hypertension.
使用纤维蛋白溶解输送导管治疗肺栓塞测量肺动脉血液动力学。
Adv Respir Med. 2022 Nov 23;90(6):483-499. doi: 10.3390/arm90060055.
4
Right Ventricle Remodeling in Chronic Thromboembolic Pulmonary Hypertension.慢性血栓栓塞性肺动脉高压中的右心室重塑
J Transl Int Med. 2022 Jul 2;10(2):125-133. doi: 10.2478/jtim-2022-0027. eCollection 2022 Jun.
5
Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations.发展中国家的肺动脉高压:诊断时间的限制因素、专用药物及因地制宜的建议
Afr J Thorac Crit Care Med. 2022 May 5;28(1). doi: 10.7196/AJTCCM.2022.v28i1.176. eCollection 2022.
6
Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?可溶性ST2作为经导管主动脉瓣置换术患者肺动脉高压风险评估的潜在生物标志物?
Life (Basel). 2022 Mar 8;12(3):389. doi: 10.3390/life12030389.
7
Circulating Blood-Based Biomarkers in Pulmonary Hypertension.肺动脉高压中基于血液的循环生物标志物
J Clin Med. 2022 Jan 13;11(2):383. doi: 10.3390/jcm11020383.
8
Pulmonary Hypertension: Diagnosis and Management.肺动脉高压:诊断与管理
Diagnostics (Basel). 2021 Jun 9;11(6):1066. doi: 10.3390/diagnostics11061066.
可溶性ST2在成人肺动脉高压中的预后价值
J Clin Med. 2019 Sep 20;8(10):1517. doi: 10.3390/jcm8101517.
4
ST2 in Heart Failure.心力衰竭中的ST2
Circ Heart Fail. 2018 Dec;11(12):e005582. doi: 10.1161/CIRCHEARTFAILURE.118.005582.
5
Chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01915-2018. Print 2019 Jan.
6
Vascular Injury Is a Major Cause of Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension.血管损伤是慢性血栓栓塞性肺动脉高压患者球囊肺动脉成形术后肺损伤的主要原因。
Circ Cardiovasc Interv. 2018 Dec;11(12):e005884. doi: 10.1161/CIRCINTERVENTIONS.117.005884.
7
Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy.球囊肺动脉成形术治疗肺血管成形术后残留或复发性肺动脉高压。
Int J Cardiol. 2019 Mar 1;278:232-237. doi: 10.1016/j.ijcard.2018.10.066. Epub 2018 Oct 25.
8
Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压期间高敏心肌肌钙蛋白 T 的动态变化。
PLoS One. 2018 Sep 25;13(9):e0204683. doi: 10.1371/journal.pone.0204683. eCollection 2018.
9
A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension.可溶性致瘤性抑制因子2(sST2)与肺动脉高压临床结局的荟萃分析。
J Geriatr Cardiol. 2017 Dec;14(12):766-771. doi: 10.11909/j.issn.1671-5411.2017.12.007.
10
N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.N 末端 pro-B 型利钠肽在慢性血栓栓塞性肺动脉高压球囊肺血管成形术后的监测作用。
J Heart Lung Transplant. 2018 May;37(5):639-646. doi: 10.1016/j.healun.2017.12.006. Epub 2017 Dec 8.